

Change of Management of OCC Shareholding

- Venture capital fund manager Stone Ridge Ventures has transferred management of a parcel of Orthocell shares to its beneficial owner, AustralianSuper
- AustralianSuper has been the beneficial owner of the parcel of shares managed by Stone Ridge Ventures and that ownership remains unchanged
- AustralianSuper is Australia's largest industry superannuation fund¹ and will now manage its investment in Orthocell directly

Perth, Australia; 26 August 2019: Regenerative medicine company Orthocell Limited (ASX:OCC, "Orthocell" or the "Company") today announced that venture capital fund manager Stone Ridge Ventures has transferred management of a parcel of Orthocell shares to its beneficial owner, AustralianSuper.

AustralianSuper has been the beneficial owner of the parcel of shares managed by Stone Ridge Ventures (see the announcement of 17 May 2019) and that remains unchanged following this transfer. Mr Matthew Callahan was an investment manager with Stone Ridge Ventures and became a director of Orthocell. He has historically disclosed his interest in Stone Ridge Ventures and therefore his indirect interest in the parcel of shares they managed for AustralianSuper.

Chairman of Orthocell, Stewart Washer, said: *"We are very grateful for Stone Ridge Ventures' strong support of Orthocell in the development of one of the world's leading regenerative medicine companies. We now look forward to working with AustralianSuper directly as a shareholder, as we continue to advance the Company's CelGro® and Ortho-ATI® platforms."*

- ENDS -

For more information, please contact:

¹ <https://www.australiansuper.com/about-us>



General & Investor enquiries

Paul Anderson

Orthocell Limited

Managing Director

P: +61 8 9360 2888

E: paulanderson@orthocell.com.au

Media enquiries

Haley Chartres

Hales2 Consultancy

P: +61 423 139 163

E: haley@h-squared.com.au

About Orthocell Limited

Orthocell is a regenerative medicine company focused on regenerating mobility for patients by developing products for the repair of a variety of soft tissue injuries. Orthocell's portfolio of products include TGA-licensed cell therapies Autologous Tenocyte Implantation (Ortho-ATI[®]) and Autologous Chondrocyte Implantation (Ortho-ACI[®]), which aim to regenerate damaged tendon and cartilage tissue. Orthocell is moving forward with clinical studies designed to assist in the US (FDA) approval process and has completed its pre-IND meetings with the FDA. The Company's other major product is the CelGro[®] platform technology, a collagen medical device which facilitates tissue repair and healing in a variety of orthopaedic, reconstructive and surgical applications. Orthocell recently received European regulatory approval (CE Mark) for CelGro[®]. The collagen medical device can now be marketed and sold within the European Union for a range of dental bone and soft tissue regeneration procedures and is being readied for first approval in the US and AUS.

For more information on Orthocell, please visit www.orthocell.com.au or follow us on Twitter [@OrthocellLtd](https://twitter.com/OrthocellLtd) and LinkedIn www.linkedin.com/company/orthocell-ltd

